Sanofi's Lixisenatide/Lantus Combo Could Be A Critical Growth Driver
This article was originally published in The Pink Sheet Daily
Executive Summary
During business update, French pharma outlines market of 9 million potential patients for the drug combo.
You may also be interested in...
Lixisenatide Gains Evidence Of A Weight Loss Benefit
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.
Lixisenatide Gains Evidence Of A Weight Loss Benefit
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.